FDA Greenlights First Gene Therapy for LAD-I: A Latest Era for Rare Disease Treatment
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved Kresladi (marnetegragene autotemcel), a gene therapy developed by Rocket Pharmaceuticals, for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). This approval marks the first FDA-approved gene therapy specifically targeting this ultra-rare genetic immune disorder, offering a potential lifeline to children facing life-threatening infections.
Understanding LAD-I and the Impact of Kresladi
Severe LAD-I is caused by mutations in the ITGB2 gene, hindering the ability of white blood cells to effectively fight infections. Without treatment, children with LAD-I often succumb to recurrent and fatal bacterial and fungal infections in early childhood. The standard treatment, allogeneic hematopoietic stem cell transplant, isn’t always feasible, particularly when a matched sibling donor isn’t available.
Kresladi utilizes a patient’s own blood stem cells, genetically modified to introduce functional copies of the ITGB2 gene. This one-time treatment aims to correct the underlying genetic defect, enabling the immune system to function properly. The FDA’s approval specifically covers pediatric patients without a suitable HLA-matched sibling donor.
A Rocky Road to Approval and the Future of Gene Therapy
The path to approval wasn’t without hurdles. Rocket Pharmaceuticals initially faced rejection from the FDA in 2024 due to manufacturing concerns. However, the company successfully addressed these issues and resubmitted its Biologics License Application (BLA), receiving acceptance in October 2025 with a PDUFA date of March 28, 2026 – ultimately resulting in approval on March 26, 2026.
While Kresladi represents a significant breakthrough, its financial impact may be limited due to the rarity of LAD-I, affecting approximately one in a million people, with an estimated 25 new cases annually. Despite the high cost expected for this one-time treatment, the little patient population suggests it won’t turn into a blockbuster drug.
The Broader Implications for Rare Disease Treatment
Kresladi’s approval signals a growing acceptance of gene therapies for rare diseases. The FDA demonstrated a willingness to exercise regulatory flexibility, considering small patient populations and all available evidence during the review process. This approach is crucial for accelerating the development and approval of treatments for conditions with limited research and patient numbers.
This approval builds on the momentum of other recent gene therapy approvals, demonstrating the potential of these innovative therapies to address previously untreatable conditions. It also highlights the importance of continued investment in research and development of gene therapies for a wider range of rare diseases.
What’s Next for Rocket Pharmaceuticals?
Rocket Pharmaceuticals is now focused on making Kresladi available to patients who require it most. The company is also eligible for a Rare Pediatric Disease Priority Review Voucher, which can be sold or used to expedite the review of another drug application.
FAQ
What is LAD-I?
LAD-I is a rare genetic immune deficiency caused by mutations in the ITGB2 gene, preventing white blood cells from effectively fighting infections.
How does Kresladi perform?
Kresladi uses a patient’s own blood stem cells, genetically modified to correct the ITGB2 gene defect.
Is Kresladi a cure for LAD-I?
Kresladi aims to provide a long-term correction of the genetic defect, potentially eliminating the need for ongoing treatment. However, long-term follow-up studies are needed to confirm its durability.
Who is eligible for Kresladi?
Kresladi is approved for pediatric patients with severe LAD-I who do not have a matched sibling donor for stem cell transplant.
What is the cost of Kresladi?
The cost of Kresladi has not been publicly disclosed, but gene therapies are generally extremely expensive.
Did you understand? The FDA’s acceptance of the BLA resubmission for Kresladi was announced on October 14, 2025.
Pro Tip: Stay informed about the latest advancements in gene therapy by following reputable sources like the FDA and organizations dedicated to rare disease research.
Want to learn more about groundbreaking medical advancements? Explore our other articles on innovative therapies and rare disease research.
- Alberta Keeps $100 COVID-19 Vaccine Fee Ahead of Fall Flu Campaign
- Social Media Driving Misuse of Alzheimer’s Blood Tests
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)